Indivior Pharmaceuticals (INDV) Cash from Investing Activities (2024 - 2026)
Indivior Pharmaceuticals (INDV) posted quarterly Cash from Investing Activities of -$19.0 million for Q1 2026, down 280.0% year-over-year from $10.6 million in Q1 2025, and up 20.83% quarter-over-quarter from -$24.0 million in Q4 2025.
Indivior Pharmaceuticals (INDV) Cash from Investing Activities (2024 - 2026) Analysis & Trends
Indivior Pharmaceuticals' Cash from Investing Activities history runs 3 years deep, the most recent figure standing at -$19.0 million for Q1 2026.
- In Q1 2026, Cash from Investing Activities fell 280.0% year-over-year to -$19.0 million; the TTM figure through Mar 2026 stood at -$80.0 million (down 305.13% YoY), while the FY2025 annual figure was -$66.0 million, down 195.65% from the prior year.
- Cash from Investing Activities for Q1 2026 stood at -$19.0 million, up from -$24.0 million in the prior quarter.
- The five-year high for Cash from Investing Activities was $35.0 million in Q3 2024, with the low at -$24.0 million in Q4 2025.
- The 3-year median for Cash from Investing Activities is -$5.0 million (2025), against an average of -$1.8 million.
- Peak annual rise in Cash from Investing Activities reached 120.0% in 2025, while the deepest fall reached 1800.0% in 2025.
- Indivior Pharmaceuticals' Cash from Investing Activities stood at $8.0 million in 2024, then plunged by 400.0% to -$24.0 million in 2025, then increased by 20.83% to -$19.0 million in 2026.
- Business Quant data shows INDV's Cash from Investing Activities at -$19.0 million in Q1 2026, -$24.0 million in Q4 2025, and -$20.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | -491.00 Mn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | -300.00 Mn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | -550.24 Mn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 87.50 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | -51.60 Mn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | -135.40 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | -110.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Indivior Pharmaceuticals | 4.51 Bn | 4.29 Bn | 294.00 Mn | -8.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -8.00 Mn |
| Jun 30, 2026 | -8.00 Mn |
| Mar 31, 2026 | -19.00 Mn |
| Mar 31, 2026 | -19.00 Mn |
| Dec 31, 2025 | -24.00 Mn |
| Dec 31, 2025 | -24.00 Mn |
| Sep 30, 2025 | -20.00 Mn |
| Sep 30, 2025 | -20.00 Mn |
| Jun 30, 2025 | -17.00 Mn |
| Jun 30, 2025 | -17.00 Mn |
| Mar 31, 2025 | -5.00 Mn |
| Mar 31, 2025 | -5.00 Mn |
| Dec 31, 2024 | 8.00 Mn |
| Dec 31, 2024 | 8.00 Mn |
| Sep 30, 2024 | 35.00 Mn |
| Sep 30, 2024 | 35.00 Mn |
| Jun 30, 2024 | 1.00 Mn |
| Jun 30, 2024 | 1.00 Mn |
| Mar 31, 2024 | 25.00 Mn |
| Mar 31, 2024 | 25.00 Mn |